These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 22383790)

  • 1. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma.
    Oki Y; Copeland A; Hagemeister F; Fayad LE; Fanale M; Romaguera J; Younes A
    Blood; 2012 Mar; 119(9):2171-2. PubMed ID: 22383790
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma.
    Hwang JJ; Kuruvilla J; Mendelson D; Pishvaian MJ; Deeken JF; Siu LL; Berger MS; Viallet J; Marshall JL
    Clin Cancer Res; 2010 Aug; 16(15):4038-45. PubMed ID: 20538761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis.
    Parikh SA; Kantarjian H; Schimmer A; Walsh W; Asatiani E; El-Shami K; Winton E; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):285-9. PubMed ID: 20709666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.
    O'Brien SM; Claxton DF; Crump M; Faderl S; Kipps T; Keating MJ; Viallet J; Cheson BD
    Blood; 2009 Jan; 113(2):299-305. PubMed ID: 18931344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies.
    Schimmer AD; O'Brien S; Kantarjian H; Brandwein J; Cheson BD; Minden MD; Yee K; Ravandi F; Giles F; Schuh A; Gupta V; Andreeff M; Koller C; Chang H; Kamel-Reid S; Berger M; Viallet J; Borthakur G
    Clin Cancer Res; 2008 Dec; 14(24):8295-301. PubMed ID: 19088047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia.
    Arellano ML; Borthakur G; Berger M; Luer J; Raza A
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):534-9. PubMed ID: 25052051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obatoclax mesylate : pharmacology and potential for therapy of hematological neoplasms.
    Joudeh J; Claxton D
    Expert Opin Investig Drugs; 2012 Mar; 21(3):363-73. PubMed ID: 22324354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells.
    Li J; Viallet J; Haura EB
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):525-34. PubMed ID: 17505826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GX15-070 (Obatoclax), a Bcl-2 family proteins inhibitor engenders apoptosis and pro-survival autophagy and increases Chemosensitivity in neuroblastoma.
    Cournoyer S; Addioui A; Belounis A; Beaunoyer M; Nyalendo C; Le Gall R; Teira P; Haddad E; Vassal G; Sartelet H
    BMC Cancer; 2019 Oct; 19(1):1018. PubMed ID: 31664947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.
    Pérez-Galán P; Roué G; López-Guerra M; Nguyen M; Villamor N; Montserrat E; Shore GC; Campo E; Colomer D
    Leukemia; 2008 Sep; 22(9):1712-20. PubMed ID: 18596739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
    Peter B; Cerny-Reiterer S; Hadzijusufovic E; Schuch K; Stefanzl G; Eisenwort G; Gleixner KV; Hoermann G; Mayerhofer M; Kundi M; Baumgartner S; Sperr WR; Pickl WF; Willmann M; Valent P
    J Leukoc Biol; 2014 Jan; 95(1):95-104. PubMed ID: 24052572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.
    Godfrey J; Bishop MR; Syed S; Hyjek E; Kline J
    J Immunother Cancer; 2017; 5():11. PubMed ID: 28239465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of relapsed Hodgkin lymphoma after autologous stem cell transplantation].
    Illés Á; Simon Z; Udvardy M; Magyari F; Jóna Á; Miltényi Z
    Orv Hetil; 2017 Aug; 158(34):1338-1345. PubMed ID: 28823212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
    Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microarray determination of Bcl-2 family protein inhibition sensitivity in breast cancer cells.
    Hudson SG; Halleran DR; Nevaldine B; Shapiro A; Hutchison RE; Hahn PJ
    Exp Biol Med (Maywood); 2013 Feb; 238(2):248-56. PubMed ID: 23576806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Novel treatment options in relapsed and refracter Hodgkin lymphomas].
    Illés Á; Jóna Á; Simon Z; Udvardy M; Miltényi Z
    Orv Hetil; 2015 Nov; 156(45):1824-33. PubMed ID: 26522856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Refractory and Relapsed Hodgkin Lymphoma With Autologous Stem-Cell Transplantation: A Single Institution Experience.
    Wali R; Saeed H; Patrus N; Javed S; Khan SJ
    J Glob Oncol; 2019 Nov; 5():1-6. PubMed ID: 31756138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panobinostat shows efficacy in Hodgkin lymphoma.
    Cancer Discov; 2012 Jun; 2(6):OF8. PubMed ID: 22684466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
    Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
    Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.
    Oki Y; Fanale M; Romaguera J; Fayad L; Fowler N; Copeland A; Samaniego F; Kwak LW; Neelapu S; Wang M; Feng L; Younes A
    Br J Haematol; 2015 Nov; 171(4):463-70. PubMed ID: 26213141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.